While Takeda Pharmaceutical Co. Ltd.'s $62bn acquisition of Shire PLC was formally completed in the first week of 2019, the ramifications continued to be felt over the following 12 months, as the enlarged Japanese firm sought to shape a combined operation it sees as truly globally competitive in its chosen focus areas.
Elsewhere in the corporate sector, it was also largely about strategic positioning. In the cases of Daiichi Sankyo Co. Ltd. and Sumitomo Dainippon Pharma Co. Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?